Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05159518 | A Study of PRT2527 in Participants With Advanced Solid Tumors | completed | Phase 1 | 30 | Prelude TherapeuticsINDUSTRY | 1 | Dec 11, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02949076 | Skeletal Muscle Atrophy and Dysfunction in Human Cancer | completed | N/A | 11 | University of VermontOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02183883 | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity(DARWIN1) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | completed | Phase 3 | 492 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02693080 | CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy | completed | Phase 1 | 19 | Stanford UniversityOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03706625 | Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment(IDeATIon) | completed | — | 201 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04105153 | Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC | completed | — | 400 | Thoraxklinik-Heidelberg gGmbHOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT04204473 | A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation | completed | Phase 1 | 105 | TYK Medicines, IncINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04229381 | Resiliency Among Older Adults Receiving Lung Cancer Treatment(ROAR-LCT) | completed | N/A | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | completed | Phase 3 | 452 | PfizerINDUSTRY | 7 | Nov 14, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02407327 | Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling(2012/52) | completed | — | 215 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT01401907 | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | completed | N/A | 351 | Massachusetts General HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03493789 | Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy | completed | Phase 1 | 19 | Emory UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03434418 | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | completed | Phase 2 | 17 | Duke UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04825873 | A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China | completed | — | 3,102 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02426658 | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02904954 | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04148066 | ctDNA Guided Treatment of Early Resistance to Targeted Treatment(TATIN) | completed | N/A | 104 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT02947386 | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02864251 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy(CheckMate722) | completed | Phase 3 | 367 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2023 | clinicaltrials |
| NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT03010657 | Modifying Your Diet to Support Muscle During Cancer Treatment. | completed | N/A | 37 | University of AlbertaOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | completed | Phase 2 | 93 | Nasser Hanna, M.D.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05908799 | Emulation of the KEYNOTE-189 Trial Using Electronic Health Records | completed | — | 1,854 | Aetion, Inc.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05419700 | A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion(ermEX-20) | completed | — | 76 | TakedaINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05933044 | RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada(RELEVANCE) | completed | — | 662 | AstraZenecaINDUSTRY | 1 | Sep 5, 2023 | clinicaltrials |
| NCT03559647 | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | completed | — | 358 | Hoffmann-La RocheINDUSTRY | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06015815 | The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT | completed | — | 21 | Ankara UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT04345146 | Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC | completed | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03083808 | Phase II Trial of Continuation Therapy in Advanced NSCLC | completed | Phase 2 | 35 | Greg Durm, MDOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03513666 | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment(JS001) | completed | Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 23, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Dec 11, 2023source: clinicaltrials